Hologic cites currency headwinds for reduced FY25 revenue guidance

We are reducing our full-year revenue guidance based mainly on currency headwinds and weakness in breast health capital sales, which are outweighing strength in our U.S. diagnostics business,” said Karleen Oberton, Hologic’s (HOLX) Chief Financial Officer. “At the same time, we are maintaining our full-year guidance for non-GAAP EPS based on strong profitability and execution of our capital allocation strategy.”